Navigation Links
Christof von Kalle, M.D., Ph.D. receives Pioneer Award

New Rochelle, NY, July 1, 2014Christof von Kalle, MD, PhD (National Center for Cancer Research, Heidelberg, Germany) began his medical and research career with a focus on oncology and virology. He subsequently devoted much of his efforts to studying the use of viral vectors to deliver therapeutic genes into host cells and understanding the mechanisms of insertional mutagenesis. In recognition of his leadership and accomplishments, Dr. von Kalle has received a Pioneer Award from Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Human Gene Therapy is commemorating its 25th anniversary by bestowing this honor on the leading 12 Pioneers in the field of cell and gene therapy selected by a blue ribbon panel* and publishing a Pioneer Perspective by each of the award recipients. The Perspective by Dr. von Kalle is available on the Human Gene Therapy website.

In "Vector Integration and Tumorigenesis," Dr. von Kalle recalls his early experiences working with retroviral vectors and the growing body of knowledge that was developing about their ability to cause mutations at the sites where they integrated into the host cell genome. He discusses the teamwork, intensive research, and technology advances that led to a growing understanding of the link between vector insertion, mutation, and malignant transformation of cells. Tracing the progress of the field forward to the present and looking to the future, Dr. von Kalle comments on the revolutionary impact that next generation sequencing technologies, molecular tools and techniques, and omics studies are having on gene therapy.

"The level of sophistication that Dr. von Kalle has brought to the analysis of vector integration is truly remarkable," says James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia. "This has established a solid scientific foundation to a critically important performance feature of retro- and lenti-based vectors."


Contact: Kathryn Ruehle
Mary Ann Liebert, Inc./Genetic Engineering News

Related biology news :

1. James Wilson, M.D., Ph.D. receives Pioneer Award
2. Huma Rana, M.D., receives 2014 Richard King Award for best publication, Genetics in Medicine
3. Xiangling Wang, M.D., Ph.D. receives Pfizer/ACMG Foundation Clinical Genetics Fellowship
4. Beth Israel Deaconess Medical Centers Harold F. Dvorak, M.D., wins Gairdner Award
5. JAX President and CEO Edison Liu, M.D., to receive Chen Award from HUGO
6. Ronald Crystal, M.D., receives Pioneer Award
7. Professor Sir David Weatherall, M.D., recieves 2013 Wallace H. Coulter Award
8. Frederic Bushman, Ph.D. receives Pioneer Award for advancing therapeutic gene delivery methods
9. Simon Levin, Ph.D., awarded prestigious 2014 Tyler Prize for Environmental Achievement
10. Jackson Laboratory researcher Gareth Howell, Ph.D., receives Lewis Rudin Glaucoma Prize
11. Joseph Glorioso, Ph.D., receives Pioneer Award
Post Your Comments:
Related Image:
Christof von Kalle, M.D., Ph.D. receives Pioneer Award
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology: